price close busi januari
biotech discov
invent manufactur commerci medicin
treat seriou diseas
upsid dupix base asthma survey
dupix gain higher share expect asthma
rais us peak sale estim dupix asthma
ex-u base survey allergist
pulmonologist internist primari care physician us
number us ex-u consensu dupix asthma
expect signific gain xolair-tr sever asthma popul market
opportun estim dupix us ex-u also see
us opportun treat patient us opportun oral
survey say doctor prefer dupix vs xolair base dose profil
base survey studi believ dupix strong potenti convert
xolair share potenti survey studi data show allergist
would prescrib dupix xolair moder sever asthma patient
pulmonologist show prefer howev note pulmonologist
would switch xolair dupix examin dupix administr
profil includ at-hom self-administr
oral corticosteroid treatment modest import opportun dupix
oral corticosteroid repres prescrib therapi sever asthma
view key segment dupix given eosinophil restrict appli also xolair
specif indic oral corticosteroid depend patient final physician
strong incent reduc long-term oral steroid use provid import
opportun dupix
fda approv antagonist requir in-clin administr healthcar provid
wherea dupix self-administ home provid meaning market
opportun dupix agent prescrib sever asthma patient
base survey survey data show physician prefer dupix self-
administr profil thu suggest dupix could convert consider
patient share therapi
maintain hold rate price target believ dupix
strong posit captur meaning share xolair sever asthma
market concern eylea keep us hold also view oral corticosteroid-
depend patient patient segment growth dupix sinc patient
group indic present xolair label rais us dupix estim
asthma rais eu estim
rais ww total dupix revenu
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
survey say expect dupix captur
xolair share
at-hom dose dupix reson physician xolair
survey suggest allergist pulmonologist would strongli prefer
dupix treat sever moder asthma base clinic
administr profil sever asthma moder asthma
suggest meaning uptak dupix market segment
interestingli allergist initi show stronger prefer dupix vs
pulmonologist vs look clinic profil howev
administr profil shown allergist pulmonologist show
strong prefer dupix allergist pulmonologist
figur pulmonologist allergist prefer base clinic administr profil xolair dupix
pulmonologist product prefer suggest would like convert current
xolair patient dupix given dupix at-hom self-inject profil
convers thesi support product convers switch pattern
observ pulmonologist would switch product prefer view
administr profil time sever asthma patient
moder asthma switch xolair dupix sever
asthma moder asthma
figur pulmonologist allergist therapi convers pattern compar administr profil xolair dupix
figur xolair convers dupix
provid typeasthma base clinic profileprefer base admin profileprovid typeasthma severityswitch admin profilexolair dupixentdupix directionprovid typeasthma severityiniti prefer xolairswitch dupix
us opportun sever patient alon
util survey result combin asthma market model estim
us market opportun dupix sever asthma base current usag
xolair drug oral corticosteroid view dupix see
heaviest usag sever patient treatment
physician util xolair sever patient key target dupix
survey suggest physician util xolair sever patient
view first key market dupix interestingli xolair usag vari
substanti among allergist pulmonologist primari physician
slightli lower among internist
market also opportun
approxim sever asthma patient receiv biolog therapi base
survey given dupix at-hom administr think drug
take share well fda approv drug requir administr
healthcar profession wherea dupix given patient home
oral corticosteroid opportun also interest sever patient
final survey look oral corticosteroid usag physician sever asthma
patient note share specifi long-term sustain oral
corticosteroid use slightli cautiou opportun
nonetheless believ dupix use
sever asthma patient focu dupix
project see gina step sever patient regardless
eosinophil count key driver dupix growth us ex-u asthma
market gina step patient typic treat anti-ig
tiotropium add-on therapi would receiv oral corticosteroid addit
add-on show total market opportun us
alon dupix
us asthma step sever persist treatment oral annual cost per patient effect revenu per market opportun oral total us gina step market figur gina step sever persist asthma market potenti eu market
eu asthma step sever persist treatment oral annual cost per patient effect revenu per market opportun oral total eu gina step market
xolair segment key opportun us eu
dupix take signific share among sever patient xolair due
dupix fev benefit conveni home administr benefit
survey pulmonologist allergist internist pcp show
xolair use sever asthma patient patient receiv
oral corticosteroid and/or laba pulmonologist allergist
similar treatment pattern across therapi class except oral corticosteroid
pulmonologist prescrib rate doubl allergist vs
estim potenti opportun dupix us
eu assum adher discount rebat
us adher discount rebat eu arriv
estim calcul total number treat patient xolair multipli
dupix price either us europ multipli adher substract
discount rebat
figur current therapi breakdown survey sever patient
drug opportun us eu
dupix requir in-offic administr
dupix self-administ home patient wherea inhibitor
approv asthma must given physician offic suggest dupix may
take share pulmonologist allergist also indic
sever asthma patient treat antagonist examin
antagonist nucala clinqair fasenra indic sever asthma
eosinophil phenotyp similar dupix howev note
antagonist administ healthcar provid vs dupix self-
administr profil particularli clinqair reslizumab black box label
anaphylaxi similar xolair thu expect dupix captur patient share
antagonist gina step patient opportun us
eu assum adher discount rebat us
adher discount rebat eu
physician typeinh corticosteroidslabasleukotrien modifiersor corticosteroidsanti igeanti figur agent asthma treatment indic administr
oral corticosteroid opportun us eu
survey data show allergist pulmonologist prescrib oral
corticosteroid sever persist asthma patient respect
sinc dupix indic oral corticosteroids-depend asthma wherea xolair
indic asthma inadequ control inhal corticosteroid expect
captur consider market share oral corticosteroid segment given
physician would incentiv reduc difficult-to-manag asthma patient
particularli younger patient depend long-term oral corticosteroid
could lead suppress immun bone-loss relat complic estim
potenti opportun opportun us eu
dupix assum adher discount rebat
us adher discount rebat eu
gina step patient exacerb
upsid dupix
lastli expect dupix captur market share gina step patient
eosinophil count cells/ul exacerbations/year sinc
patient manag inhal corticosteroid ic long-act beta agonist
laba inexpens rel dupix
howev believ self-administr profil eosinophil-correl
exacerb reduct would lead physician adopt patient
eosinophil asthma expect peak market share gina step patient
eosinophils/ul us peak share eu
expect low dupix usag moder
model low usag dupix among moder asthma patient mainli
gener manag easier administ inhal medic
suspect physician patient forego ad dupix asthma
symptom worsen thu assum dupix share us among
moder asthma patient gina step eosinophil count cells/ul
assum usag among moder patient europ
nucala mepolizumab cinqair reslizumab fasenra benralizumab asthma indicationadd-on mainten treatment sever asthma eosinophil phenotypeadd-on mainten treatment sever asthma eosinophil phenotypeadd-on mainten treatment sever asthma eosinophil phenotypepati olderadministr administ healthcar profession reconstitut requiredadminist healthcar profession prepar manag anaphylaxisadminist healthcar profession pre-filled syringewarningnoneanaphylaxisnon regeneron pharmaceut
asthma model base claim data gina
built asthma market model base global initi asthma gina
treatment see includ segment base global initi asthma
gina step also util two retrospect claim data analys base
insur claim us uk asthma patient consid gina step
moder asthma gina step sever asthma also segment
gina step eosinophil count cells/ul cells/ul specifi
dupix label base review insur reimburs approv
therapi asthma eosinophil phenotyp believ cells/ul
appropri cell count
figur global initi asthma gina treatment step
util two claims-bas data analys model treatment asthma market
studi publish base patient us impact
databas second studi publish us base patient
im pharmetr claim databas effect calcul treatment
share base gina treatment step take averag two studi
larger studi publish examin patient us
asthma look exacerb studi util impact databas examin
insur claim us patient unlik prior studi studi look
treatment index pre-treat period impact base studi
estim higher percentag patient gina step suspect
patient treat entir time period studi
estim gina step gina step gina step gina
figur gina step patient exacerb year
second studi publish util random sampl im
util analysi follow year studi util
gina treatment step describ patient highest asthma treatment within
day treatment period importantli patient treatment entir studi
period exclud treatment level describ patient receiv
treatment given period receiv treatment least
one period averag year follow-up period studi estim
diagnos asthma patient gina
step treatment respect
therefor model patient receiv treatment diagnos asthma
patient receiv gina step base averag
two studi util also use averag two studi estim
treatment share gina step gina step gina step
gina step
figur longitudin claim analysi asthma treatment step pattern
campbel et al american journal respiratori critic medicin
final model diagnos asthma patient persist sever base
sanofi decemb investor present cite datamonitor
asthma report jan asthma epidemiolog eur resp
fy asthma us marketdiagnos adult asthmat year diagnos adolesc asthmat year diagnos pediatr asthmat year step step step step step persist persist gina step gina step gina step gina step gina step treat persist gina step gina step gina step gina step gina step treat persist gina step gina step gina step gina step gina step eosinophil eosinophil eosinophil figur us asthma market model cont
fy asthma us markettreat sharemoder asthma treat gina step asthma treat gina step cells/ul adultswith asthma treat gina step asthma treat gina step treat patientsmoder asthma treat gina step cells/ul adults- adolescents- pediatrics- sever asthma treat gina step cells/ul adults- exacerbation/year- exacerbation/year- adolescents- exacerbation/year- exacerbation/year- pediatrics- exacerbation/year- exacerbation/year- sever asthma treat gina step cells/ul adults- adolescents- pediatrics- sever asthma treat gina step cells/ul adults- adolescents- pediatrics- total dupix treat patients- figur us asthma market model cont
fy asthma us markettot dupix treat patients- dupix per mg dose per per annual cost per revenu per us dupilumab demand uncontrol mod/sever asthma- discount rebates- discount rebat build drawdown us dupilumab revenu uncontrol mod/sever asthma- figur eu asthma market model
fy asthma eu marketdiagnos adult asthmat year diagnos adolesc asthmat year diagnos pediatr asthmat year treatmentgina step step step step step persist persist gina step gina step gina step gina step gina step treat persist gina step gina step gina step gina step gina step treat persist gina step gina step gina step gina step gina step eosinophil eosinophil eosinophil figur eu asthma market model cont
fy asthma eu markettreat sharemoder asthma treat gina step asthma treat gina step cells/ul adultswith asthma treat gina step asthma treat gina step treat patientsmoder asthma treat gina step cells/ul adults- adolescents- pediatrics- sever asthma treat gina step cells/ul adults- exacerbation/year- exacerbation/year- adolescents- exacerbation/year- exacerbation/year- pediatrics- exacerbation/year- exacerbation/year- sever asthma treat gina step cells/ul adults- adolescents- pediatrics- sever asthma treat gina step cells/ul adults- adolescents- pediatrics- total dupix treat patients- figur eu asthma market model cont
fy asthma eu markettot dupix treat patients- dupix per mg dose per per annual cost per revenu per eu dupilumab demand uncontrol mod/sever asthma- discount rebates- discount rebat build drawdown eu dupilumab revenu uncontrol mod/sever asthma-
rais dupix asthma estim
total
base survey result dupix asthma revis project
dupix asthma world-wide peak sale us
peak sale eu peak sale project
total dupix sale asthma us eu
us ex-u market project dupix asthma in-lin
consensu us trend higher vs consensu shown
approach market share uptak conserv
like revis growth rate accordingli dupix sale data asthma
quantifi respons survey perform
figur asthma survey question result
number asthma patient treat encount per asthma patient consid frequenc present asthma patientsalwayssometimesrarelyneverprimari frequenc physician typespulmonologistsallergistspcpinternistprimari assess sever therapi typic prescrib sever asthma patient physician typeinh corticosteroidsor corticosteroidsleukotrien sever asthma patient manag standard figur asthma survey question result cont
product like consid sever asthma patient base clinic like consid moder asthma patient base clinic like consid sever asthma patient base administr like consid moder asthma patient base administr current prescrib consid prescrib inject futur current prescrib eosinophil correl efficaci envis includ biomark test part diagnbost process figur revenu summari
fy producteyleau ex-u arcalystu ex-u revenues- net product sale book praluentu ex-u ww zaltrap- ww kevzara- us revenu probabl adjust ex-u revenu probabl adjust dupixent- us atop uncontrol asthma- ex-u atop uncontrol asthma- figur incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord
genuiti sale person author analyst whose contact inform appear front page report
fy bayer collabor technolog net product contract research other- total good option expensegross oper expensesresearch sell gener option sg collabor total oper profit loss oper profit loss incom expens invest interest incom expens loss earli extinguish debtpre-tax incom pre-tax incom tax rate tax expens benefit tax rate tax expens benefit net incom loss interest expens convert debtnon-cash interest relat convert senior notesadjust net net incom loss ep fulli ep fulli share dilut share outstand dilut share outstand figur balanc sheet
fy pharmaceut balanc sheetassetscash cash equival market secur account receiv trade account receiv sanofi account receiv bayer defer tax assets- prepaid expens current asset total current asset restrict cash market secur market secur properti plant equip cost net accumul defer tax asset total asset liabil account payabl accru expens capit leas oblig defer revenu sanofi current portion defer revenu current portion facil leas oblig current portion current total current liabil convert senior notes- defer revenu sanofi defer revenu facil leas oblig long term liabil total liabil commit conting total stockhold equiti total liabil stockhold equiti figur statement cash flow
fy statement flow net incom adj reconcil net loss net cash use provid oper activities- depreci non-cash compens non-cash interest expense- loss earli extinguish debt- net realiz loss gain market securities- non-cash charg expens defer chang asset liabil decreas increas account increas increas decreas prepaid expens decreas increas defer increas account payabl accru expens total flow purchas market sale matur market purchas restrict market securities- decreas increas restrict cash- capit increas restrict flow repurchas repay note payabl proce connect facil leas payment connect facil leas net proce issuanc common payment common stock tender employe tax payment connect reduct outstand warrants- net proce issuanc convert debt- proce connect issuanc warrants- payment connect capit leas obligations- payment connect convert debt- payment connect purchas convert note hedges- excess tax benefit stock-bas compensation- repurchas common flow net increas cash cash cash equival begin cash equival end regeneron
